skip to Global Navigation Bar
skip to main content
HOME
CONTACT US
SITEMAP
KOREAN
Global Business
Introduction
Strategy
Manufacturing
Contact Us
R&D
Introduction
Global R&D Centers
R&D Organization
Pipeline
CDMO
Introduction
Manufacturing Sites
Business Model
Service Range
Products
Global Brand
Products Search
In-License
Introduction
Strategy
No.1 Position
Core-Competency
Licensed Products
Partnership
Investors
Management information
Financial information
Stock condition
IR information
About Us
Company Profile
CEO Message
Recruitment
Press Release
Company Profile
CEO Message
Recruitment
Press Release
News
PR Video
Home > About Us > Press Release >
News
뉴스
No
Subject
Data
210
Daewoong Pharmaceuticals strengthens CP... Extends to the entire corporate group
2016-03-31
209
Daewoong Pharmaceuticals - Daiichi-Sankyo Korea Expect sales of 30 billion won this year with Sevikar HCT
2016-03-17
208
"Effective corporation in overseas markets" Distinguished export strategy by Daewoong Pharmaceuticals
2016-02-24
207
Erdos by Daewoong Pharmaceuticals expecting a blockbuster growth with its outstanding mucolytic effects for 2016
2016-02-22
206
Daewoong Pharmaceuticals’ Daewoong Meropenem Inj. US FDA approved
2016-01-05
205
Daewoong Pharmaceutical held a pre-launch symposium on Suglat, an anti-diabetic agent, with Astellas Pharma Korea
2015-01-09
204
Daewoong Pharmaceutical is poised to evolve into a global pharmaceutical company in 2015
2015-01-02
203
Daewoong Pharmaceutical became the first in pharmaceutical industry to receive AA-grade in CP evaluation
2015-01-02
202
Daewoong Pharmaceutical was honored with Prime Minister's Award in the 11th Korea New Growth Management Award
2014-12-22
201
NABOTA, the botulinum toxin formulation of Daewoong Pharmaceutical, was named the World-Class Product of 2014
2014-12-10
1
/
2
/
3
/
4
/
5
/
6
/
7
/
8
/
9
/
10
/
News Search
subject
content
Home > About Us > Press Release > News
Home > About Us > Press Release > News